Hazel Joanne Clothier

Hazel Joanne Clothier

Auto-generated profile, based on publicly available information

Hazel Joanne Clothier

Epidemiology Informatics Group and Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2013 in Expert Review of Vaccines
Verified
Journal Article
Closed access
NCNigel W Crawford
Nigel W Crawford
HCHazel Clothier
Hazel Clothier
KHKate Hodgson
Kate Hodgson
GSGowri Selvaraj
Gowri Selvaraj
MEMee Lee Easton
Mee Lee Easton
JBJim P Buttery
Jim P Buttery
Comprehensive surveillance of adverse events following immunization (AEFI) is required to detect potential serious adverse events that may not be identified in prelicensure vaccine trials. Surveillance systems have traditionally been passive, relying upon spontaneous reporting, but increasingly active surveillance and supplemental strategies are being incorporated into vaccine safety programs. These include active screening for targeted conditions of interest (e.g., hospitalization), monitoring of new data sources and real-time methodologies to detect changes in vaccine safety data in these sources. The role of improved causality assessment in AEFI surveillance is discussed, with its important role in determining whether a temporal association may have occurred by chance alone. Strong local vaccine safety networks are required to support national immunization programs, with recent progress in developing a framework for low- and middle-income countries. Global collaboration is increasingly required to address challenges in active AEFI surveillance, particularly for rare serious adverse events.

22 December 2004 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
CBC. J. Birch
C. J. Birch
HCH. J. Clothier
H. J. Clothier
ASA. Seccull
A. Seccull
TTT. Tran
T. Tran
MCM. C. Catton
M. C. Catton
JDJulian Druce
Julian Druce
Three outbreaks of respiratory illness associated with human coronavirus HCoV-OC43 infection occurred in geographically unrelated aged-care facilities in Melbourne, Australia during August and September 2002. On clinical and epidemiological grounds the outbreaks were first thought to be caused by influenza virus. HCoV-OC43 was detected by RT–PCR in 16 out of 27 (59%) specimens and was the only virus detected at the time of sampling. Common clinical manifestations were cough (74%), rhinorrhoea (59%) and sore throat (53%). Attack rates and symptoms were similar in residents and staff across the facilities. HCoV-OC43 was also detected in surveillance and diagnostic respiratory samples in the same months. These outbreaks establish this virus as a cause of morbidity in aged-care facilities and add to increasing evidence of the significance of coronavirus infections.

1 December 2011 in Communicable Diseases Intelligence
Verified
Journal Article
Open access
PDF file
HCHazel J Clothier
Hazel J Clothier
NCNigel W Crawford
Nigel W Crawford
AKAnn Kempe
Ann Kempe
JBJim P Buttery
Jim P Buttery
State-based adverse events following immunisation (AEFI) reporting systems in Australia demonstrate marked regional differences in surveillance methodologies and reporting rates. To improve AEFI services in Victoria, Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) was established in 2007. SAEFVIC comprises a central reporting enhanced passive surveillance system integrated with clinical services. AEFI may be reported by phone, fax or on-line. Immunisation nurse specialists follow up all reports, coupled with physician review as required. Supervised re-vaccination in a hospital environment, when appropriate, helps ensure clinical support for vaccinees, families and health-care providers. The Brighton Collaboration, the Australian Immunisation Handbook and in-house case definitions are used to categorise AEFI reports. In the first 3 years (2007–2010) of operation 3,265 reports were received, describing 4,293 AEFI. The number of reports received increased annually over the 3-year period. Seventy-six per cent of AEFI met one of 52 established case definitions and the remainder were recorded verbatim: 22% of reported AEFI were considered severe. Of 1,086 persons reporting an AEFI in 2009, 356 (36%) attended for a clinical consultation and 325 (83%) were revaccinated, of which 114 were day stay or overnight patients. Enhanced passive AEFI surveillance using integrated clinical services has been shown to improve adverse event reporting with reporting rates in Victoria increasing from 2.6 per 100,000 in 2003 to 13.5 per 100,000 per annum in 2009. This report describes the SAEFVIC service model and summarises outcomes and lessons learnt in the first 3 years of operation. Commun Dis Intell 2011;35(4):295–299.

1 November 2014 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
HCHazel J Clothier
Hazel J Clothier
GSGowri Selvaraj
Gowri Selvaraj
MEMee Lee Easton
Mee Lee Easton
GLGeorgina Lewis
Georgina Lewis
NCNigel W Crawford
Nigel W Crawford
JBJim P Buttery
Jim P Buttery
Surveillance of adverse events following immunisation (AEFI) is an essential component of vaccine safety monitoring. The most commonly utilized passive surveillance systems rely predominantly on reporting by health care providers (HCP). We reviewed adverse event reports received in Victoria, Australia since surveillance commencement in July 2007, to June 2013 (6 years) to ascertain the contribution of consumer (vaccinee or their parent/guardian) reporting to vaccine safety monitoring and to inform future surveillance system development directions. Categorical data included were: reporter type; serious and non-serious AEFI category; and, vaccinee age group. Chi-square test and two-sample test of proportions were used to compare categories; trend changes were assessed using linear regression. Consumer reporting increased over the six years, reaching 21% of reports received in 2013 (P

3 January 2011 in Medical Journal of Australia
Verified
Journal Article
Closed access
PDF file
NCNigel W Crawford
Nigel W Crawford
HCHazel J Clothier
Hazel J Clothier
SESonja Elia
Sonja Elia
TLTeresa Lazzaro
Teresa Lazzaro
JRJenny Royle
Jenny Royle
JBJim P Buttery
Jim P Buttery
Objective: To quantify and characterise the reports of syncope and seizures following quadrivalent (4v) human papillomavirus (HPV) vaccination. Design and setting: Retrospective case series of notifi...

24 March 2017 in Drug Safety
Verified
Journal Article
Closed access
PDF file
HCHazel J. Clothier
Hazel J. Clothier
NCNigel W. Crawford
Nigel W. Crawford
MRMelissa Russell
Melissa Russell
HKHeath Kelly
Heath Kelly
JBJim P. Buttery
Jim P. Buttery